Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of S-1, Oral Leucovorin, Oxaliplatin, and Bevacizumab in Untreated Metastatic Colorectal Cancer
jRCT2080220850Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, folinic acid, oxaliplatin and bevacizumab in metastatic colon cancer (mCRC), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
tegafurfolinic acidoxaliplatinbevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2080220850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220850.